Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Sharp & Dohme Ltd.

Division of Merck & Co. Inc.

Latest From Merck Sharp & Dohme Ltd.

Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications

Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.

Drug Review Approvals

Roche’s Hemlibra Looking For CHMP Green Light, Crunch Time for Santhera DMD Hopeful

The first meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London, with a number of new drugs up for a marketing authorization recommendation.

Europe Approvals

UK Life Science 'Needs Manufacturing Incentives, NHS Access' After Brexit

MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.

Brexit Business Strategies

Sir John Bell: UK Life Science Pact Essential For Post-Brexit Success

Successfully piecing together the agreed life sciences sector deal calls for the UK to embrace high-risk innovation and placing the NHS at its center, says Sir John Bell who helped formulate the pact.

Brexit Business Strategies
See All

Company Information